CORT Stock News & Catalysts – Corcept Therapeutics

FEATURED

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Revenue of $340.5 million, a 64 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $249.1 million Lifyorli® product revenue of $91.4 million Reiterated 2026

Summary

Nov 3, 2026, 4:05 PM ·Business Wire

RECENT

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day

Oct 27, 2026, 4:05 PM ·Business Wire

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

Lifyorli (relacorilant) in combination with nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the more

Oct 26, 2026, 8:00 AM ·Business Wire

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Joint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications Corcept

Oct 20, 2026, 4:00 PM ·Business Wire

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR)

SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ:ERAS), DICK’S Sporting Goods, Inc. (NYSE:DKS),

Oct 9, 2026, 11:55 AM ·Globe Newswire

Corcept Announces Planned Leadership Transition

Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat

Sep 23, 2026, 8:00 AM ·Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

Sep 18, 2026, 8:00 AM ·Business Wire

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of

Sep 4, 2026, 7:15 PM ·PRNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026

Jul 29, 2026, 4:05 PM ·Business Wire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at

Jul 22, 2026, 4:05 PM ·Business Wire

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ:CORT) breached their

Jun 25, 2026, 6:41 PM ·PRNewswire

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ:CORT) breached their

Jun 17, 2026, 10:10 PM ·Globe Newswire

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

Jun 17, 2026, 4:28 PM ·Business Wire

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically

Jun 6, 2026, 4:45 PM ·Business Wire

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026, 4:33 PM ·Business Wire

Corcept Therapeutics Incorporated CORT · News